News

Flagship Pioneering took part in the financing round, which has also seen participation from new investors, including Bluwave Capital, Qatar Investment Authority (QIA), Stage 1 Ventures, and Samsung

The latest move follows a positive opinion issued by the European Medicines Agency (EMA). A precision-engineered, tetravalent death receptor 5 (DR5) agonist antibody, INBRX-109 has been designed for

Orally available bruton’s tyrosine kinase (BTK) inhibitor, orelabrutinib irreversibly binds to BTK for inducing downstream kinase inactivation and cell death. It has been designed with a single ring

Xofluza is indicated to treat acute uncomplicated influenza in healthy children aged five to less than 12 years with symptoms for not over 48 hours. The regulatory approval

The new fully synthetic fluorocycline intravenous antibiotic, xerava has been developed to use as a first-line empiric monotherapy to treat multidrug resistance (MDR) infections, such as MDR Gram-negative

The regulatory indicated the healthcare providers to use the vaccine as intradermal injection for people aged 18 years and above, who are at elevated risk for monkeypox infection.

The latest move comes after the receipt of the US Food and Drug Administration (FDA) approval in May this year for the new formulation, which includes the same

X-Chem will use the DEL services platform along with a group of new diverse lead- and drug-like small molecule compounds to help expedite the hits’ discovery and to

Kingray Capital, TigerYeah Capital, Morningside Venture Capital, and Trinity Innovation Fund joined the Series Pre-A funding, while FountainBridge Capital participated as the angel investor. Epigenic will utilise the